Dr. Roffman presented his talk, “The Prenatal Environment and Risk for Serious Mental Illness: Toward Early Common Pathways for Prevention,” at MGH Psychiatry Grand Rounds this week. Thanks to all who attended!
Our work understanding how increased exposure to folic acid through fortification may reduce schizophrenia risk was selected as one of 2018’s Leading Research Achievements by the Brain & Behavior Research Foundation! Learn more about this work and some other fantastic advances in psychiatry published this year by clicking here.
At ACNP this year? So are we! Check out poster M200 at this evening’s poster session and T195 at tomorrow’s. Hear lab PI Joshua Roffman talk about some of recent work at tomorrow’s 8:30 am mini-panel on folate and severe mental illness!
Congratulations to Dr. Hamdi Eryilmaz on his recent promotion to Instructor in the Department of Psychiatry at Harvard Medical School!
Lab principal investigator, Dr. Joshua Roffman, has been named as a co-director of the new MGH Neuroscience initiative. The initiative aims to promote collaborations within the large neuroscience clinical and research community at the MGH. Read the MGH announcement here.
Check out our recent publication in JAMA Psychiatry that suggests increased exposure to folic acid in utero may alter the trajectory of brain development in a manner that predicts reduced risk for psychosis in youth. Congratulations to lead author, Dr. Hamdi Eryilmaz!
Congratulations to co-first authors Daniel Cummings and Kevin Dowling for their paper, ‘A Cross-Sectional Study of Dietary and Genetic Predictors of Blood Folate Levels in Healthy Young Adults.’ Check out the paper here.
Congratulations to Dr. Hamdi Eryilmaz, lead author on the most recent publication from the lab: Neural determinants of human goal-directed vs. habitual action control and their relation to trait motivation. To read the manuscript, please click here
Congratulations to lab PI, Dr. Joshua Roffman, lead author on a new paper in Moelcular Psychiatry. In the paper the authors report on physiological and symptom changes in a randomized controlled trial of L-methylfolate (a more bioavailable form of folic acid) in the treatment of schizophrenia.